Article
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2018
Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler J F, Paweletz C P, Oxnard G R
Abstract excerpt
Background: Genomic analysis of plasma cell-free DNA is transforming lung cancer care; however, available assays are limited by cost, turnaround time, and imperfect accuracy. Here, we study amplicon-based plasma next-generation sequencing (NGS), rather than hybrid-capture-based plasma NGS, hypothesizing this would allow sensitive detection and monitoring of driver and resistance mutations in advanced non-small...
Topics
- Carcinoma, Non-Small-Cell Lung
- Cell-Free Nucleic Acids
- Drug Resistance, Neoplasm
- ErbB Receptors
- High-Throughput Nucleotide Sequencing
- Humans
- Lung Neoplasms
- Mutation